Search research articles
Contact Us
Filters
Showing results (11-20 of 86) with videos related to
Page
of 9
Sort By:
Diabetes Care
|
August 27, 2005
Counterpoint: visceral adiposity is not causally related to insulin resistance
John M Miles, Michael D Jensen
Expert Opinion on Pharmacotherapy
|
November 2, 2005
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes
Robert H Nelson, John M Miles
Mayo Clinic Proceedings
|
May 11, 2004
Bilateral carotid body paraganglioma
Nicholas W W Choong, John M Miles
Current Cardiology Reports
|
May 22, 2017
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
Abeer Anabtawi, Patrick M Moriarty, John M Miles
Journal of Clinical Lipidology
|
February 5, 2011
Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemia
William L Isley, John M Miles, William S Harris
Metabolism: Clinical and Experimental
|
May 23, 2006
The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitus
William L Isley, William S Harris, John M Miles
Current Diabetes Reports
|
April 23, 2014
Use of metformin in diseases of aging
John M Miles, Andrew D Rule, Barry A Borlaug
Diabetes
|
August 28, 2012
Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans
Robert H Nelson, Danielle Vlazny, Almira Smailovic, et al.
Diabetes
|
January 30, 2007
Myocardial uptake of circulating triglycerides in nondiabetic patients with heart disease
Robert H Nelson, Abhiram Prasad, Amir Lerman, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 7, 2011
Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp
Johannes D Veldhuis, Dana Erickson, John M Miles, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 86) with videos related to
Sort By:
Page
of 9
Diabetes Care
|
August 27, 2005
Counterpoint: visceral adiposity is not causally related to insulin resistance
John M Miles, Michael D Jensen
Expert Opinion on Pharmacotherapy
|
November 2, 2005
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes
Robert H Nelson, John M Miles
Mayo Clinic Proceedings
|
May 11, 2004
Bilateral carotid body paraganglioma
Nicholas W W Choong, John M Miles
Current Cardiology Reports
|
May 22, 2017
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins
Abeer Anabtawi, Patrick M Moriarty, John M Miles
Journal of Clinical Lipidology
|
February 5, 2011
Pilot study of combined therapy with ω-3 fatty acids and niacin in atherogenic dyslipidemia
William L Isley, John M Miles, William S Harris
Metabolism: Clinical and Experimental
|
May 23, 2006
The effect of high-dose simvastatin on free fatty acid metabolism in patients with type 2 diabetes mellitus
William L Isley, William S Harris, John M Miles
Current Diabetes Reports
|
April 23, 2014
Use of metformin in diseases of aging
John M Miles, Andrew D Rule, Barry A Borlaug
Diabetes
|
August 28, 2012
Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans
Robert H Nelson, Danielle Vlazny, Almira Smailovic, et al.
Diabetes
|
January 30, 2007
Myocardial uptake of circulating triglycerides in nondiabetic patients with heart disease
Robert H Nelson, Abhiram Prasad, Amir Lerman, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
April 7, 2011
Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp
Johannes D Veldhuis, Dana Erickson, John M Miles, et al.
Page
of 9